206. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality.
作者: Mingming Xiao.;Rong Tang.;Haoqi Pan.;Jing Yang.;Xuhui Tong.;He Xu.;Yanmei Guo.;Yalan Lei.;Di Wu.;Yubin Lei.;Yamei Han.;Zhilong Ma.;Wei Wang.;Jin Xu.;Xianjun Yu.;Si Shi.
来源: Gut. 2025年74卷3期410-423页
PARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in BRCA1/2 are notably rare in pancreatic cancer.
207. Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma.
作者: Yalin Tu.;Haoran Wu.;Chengpeng Zhong.;Yan Liu.;Zhewen Xiong.;Siyun Chen.;Jing Wang.;Patrick Pak-Chun Wong.;Weiqin Yang.;Zhixian Liang.;Jiahuan Lu.;Shufen Chen.;Lingyun Zhang.;Yu Feng.;Willis Wai-Yiu Si-Tou.;Baoyi Yin.;Yingnan Lin.;Jianxin Liang.;Liying Liang.;Joaquim S L Vong.;Weida Ren.;Tsz Tung Kwong.;Howard Leung.;Ka Fai To.;Stephanie Ma.;Man Tong.;Hanyong Sun.;Qiang Xia.;Jingying Zhou.;David Kerr.;Nick La Thangue.;Joseph J Y Sung.;Stephen Lam Chan.;Alfred Sze-Lok Cheng.
来源: Gut. 2025年74卷4期613-627页
Genomic screening uncovered interferon-gamma (IFNγ) pathway defects in tumours refractory to immune checkpoint blockade (ICB). However, its non-mutational regulation and reversibility for therapeutic development remain less understood.
208. Single-use scopes may reduce various environmental impacts of gastroscopy in some situations but probably not in routine practice of endoscopy units.
作者: Mathieu Pioche.;Guillaume Vidal.;Madj Ben Rejeb.;Rémi Collin.;Jérémie Jacques.
来源: Gut. 2025年74卷5期866-867页 209. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg).
作者: Llum Olmedo.;Xavier Calvet.;Emili Gené.;Dmitry S Bordin.;Irina Voynovan.;M Castro-Fernandez.;Manuel Pabón-Carrasco.;Alma Keco-Huerga.;Ángeles Perez-Aisa.;Alfredo J Lucendo.;Luís Rodrigo.;Aiman S Sarsenbaeva.;Igor B Khlinov.;Galyna Fadieienko.;Oleg Zaytsev.;Ángel Lanas.;Samuel J Martínez-Domínguez.;Enrique Alfaro.;Laimas Jonaitis.;Óscar Núñez.;Rinaldo Pellicano.;Luis Hernández.;Oleksiy Gridnyev.;Juozas Kupcinskas.;Antonio Gasbarrini.;Doron Boltin.;Yaron Niv.;Gülüstan Babayeva.;Ricardo Marcos-Pinto.;Bojan Tepes.;Marino Venerito.;Veronika Papp.;Frode Lerang.;Mārcis Leja.;Perminder S Phull.;Wojciech Marlicz.;Michael Doulberis.;Sinead M Smith.;Vladimir Milivojevic.;Lumir Kunovsky.;Antonio Mestrovic.;Tamara Matysiak-Budnik.;Halis Simsek.;Anna Cano-Català.;Ignasi Puig.;Leticia Moreira.;Pablo Parra.;Olga P Nyssen.;Francis Megraud.;Colm O'Morain.;Javier P Gisbert.; .
来源: Gut. 2024年74卷1期15-25页
Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance.
211. ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-β1 activation.
作者: Frederik Link.;Yujia Li.;Jieling Zhao.;Stefan Munker.;Weiguo Fan.;Zeribe C Nwosu.;Ye Yao.;Shanshan Wang.;Chenjun Huang.;Roman Liebe.;Seddik Hammad.;Hui Liu.;Chen Shao.;Chunfang Gao.;Bing Sun.;Natalie J Török.;Huiguo Ding.;Matthias Pa Ebert.;Honglei Weng.;Peter Ten Dijke.;Dirk Drasdo.;Steven Dooley.;Sai Wang.
来源: Gut. 2025年74卷3期424-439页
Extracellular matrix protein 1 (ECM1) serves as a gatekeeper of hepatic fibrosis by maintaining transforming growth factor-β1 (TGF-β1) in its latent form. ECM1 knockout (KO) causes latent (L) TGF-β1 activation, resulting in hepatic fibrosis with rapid mortality. In chronic liver disease (CLD), ECM1 decreases with increasing CLD severity. We investigate the regulatory role of ECM1 in TGF-β1 bioavailability and its impact on CLD progression.
214. Combined MRI, high-resolution manometry and a randomised trial of bisacodyl versus hyoscine show the significance of an enlarged colon in constipation: the RECLAIM study.
作者: Victoria Wilkinson-Smith.;Mark Scott.;Alex Menys.;Lukasz Wiklendt.;Luca Marciani.;David Atkinson.;Stefano Sansone.;Ausra Zdanaviciene.;Carol Coupland.;Charles H Knowles.;Philip Dinning.;Stuart A Taylor.;Penny Gowland.;Caroline Louise Hoad.;Maura Corsetti.;Robin C Spiller.
来源: Gut. 2024年74卷1期35-44页
Colonic motility in constipation can be assessed non-invasively using MRI.
216. IQGAP3 signalling mediates intratumoral functional heterogeneity to enhance malignant growth.
作者: Mitsuhiro Shimura.;Junichi Matsuo.;ShuChin Pang.;Nawaphat Jangphattananont.;Aashiq Hussain.;Muhammad Bakhait Rahmat.;Jung-Won Lee.;Daisuke Douchi.;Jasmine Jie Lin Tong.;Khine Myint.;Supriya Srivastava.;Ming Teh.;Vivien Koh.;Wei Peng Yong.;Jimmy Bok Yan So.;Patrick Tan.;Khay-Guan Yeoh.;Michiaki Unno.;Linda Shyue Huey Chuang.;Yoshiaki Ito.
来源: Gut. 2025年74卷3期364-386页
The elevation of IQGAP3 expression in diverse cancers indicates a key role for IQGAP3 in carcinogenesis. Although IQGAP3 was established as a proliferating stomach stem cell factor and a regulator of the RAS-ERK pathway, how it drives cancer growth remains unclear.
217. QUAIDE - Quality assessment of AI preclinical studies in diagnostic endoscopy.
作者: Giulio Antonelli.;Diogo Libanio.;Albert Jeroen De Groof.;Fons van der Sommen.;Pietro Mascagni.;Pieter Sinonquel.;Mohamed Abdelrahim.;Omer Ahmad.;Tyler Berzin.;Pradeep Bhandari.;Michael Bretthauer.;Miguel Coimbra.;Evelien Dekker.;Alanna Ebigbo.;Tom Eelbode.;Leonardo Frazzoni.;Seth A Gross.;Ryu Ishihara.;Michal Filip Kaminski.;Helmut Messmann.;Yuichi Mori.;Nicolas Padoy.;Sravanthi Parasa.;Nastazja Dagny Pilonis.;Francesco Renna.;Alessandro Repici.;Cem Simsek.;Marco Spadaccini.;Raf Bisschops.;Jacques J G H M Bergman.;Cesare Hassan.;Mario Dinis Ribeiro.
来源: Gut. 2024年74卷1期153-161页
Artificial intelligence (AI) holds significant potential for enhancing quality of gastrointestinal (GI) endoscopy, but the adoption of AI in clinical practice is hampered by the lack of rigorous standardisation and development methodology ensuring generalisability. The aim of the Quality Assessment of pre-clinical AI studies in Diagnostic Endoscopy (QUAIDE) Explanation and Checklist was to develop recommendations for standardised design and reporting of preclinical AI studies in GI endoscopy.The recommendations were developed based on a formal consensus approach with an international multidisciplinary panel of 32 experts among endoscopists and computer scientists. The Delphi methodology was employed to achieve consensus on statements, with a predetermined threshold of 80% agreement. A maximum three rounds of voting were permitted.Consensus was reached on 18 key recommendations, covering 6 key domains: data acquisition and annotation (6 statements), outcome reporting (3 statements), experimental setup and algorithm architecture (4 statements) and result presentation and interpretation (5 statements). QUAIDE provides recommendations on how to properly design (1. Methods, statements 1-14), present results (2. Results, statements 15-16) and integrate and interpret the obtained results (3. Discussion, statements 17-18).The QUAIDE framework offers practical guidance for authors, readers, editors and reviewers involved in AI preclinical studies in GI endoscopy, aiming at improving design and reporting, thereby promoting research standardisation and accelerating the translation of AI innovations into clinical practice.
218. Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohn's disease.
作者: Xiaofen Lv.;Yunqing Zeng.;Wenlong Ma.;Yuan Zheng.;Tengkai Wang.;Mingru Liu.;Di Zhang.;Lixiang Li.;Xiuli Zuo.;Yanqing Li.;Jiaoyang Lu.
来源: Gut. 2025年74卷4期686-689页 219. Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
作者: Anke M Onnekink.;Myrte Gorris.;Noor Lh Bekkali.;Philip Bos.;Paul Didden.;J Enrique Dominguez-Muñoz.;Pieter Friederich.;Emo E van Halsema.;Wouter L Hazen.;Nadine C van Huijgevoort.;Akin Inderson.;Maarten Ajm Jacobs.;Jan J Koornstra.;Sjoerd Kuiken.;Bob Ch Scheffer.;Hilbert Sloterdijk.;Ellert J van Soest.;Niels G Venneman.;Rogier P Voermans.;Thomas R de Wijkerslooth.;Janneke Wonders.;Roeland Zoutendijk.;Serge Jlb Zweers.;Paul Fockens.;Robert C Verdonk.;Roy L J van Wanrooij.;Jeanin E Van Hooft.; .
来源: Gut. 2025年74卷2期246-254页
Endoscopic retrograde cholangiopancreatography (ERCP) with fully covered self-expandable metal stent (FCSEMS) placement is the preferred approach for biliary drainage in patients with suspected distal malignant biliary obstruction (MBO). However, FCSEMS placement is associated with a high risk of post-ERCP pancreatitis (PEP). Endoscopic sphincterotomy prior to FCSEMS placement may reduce PEP risk.
220. Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
作者: David Z Pan.;Cameron M Soulette.;Abhishek Aggarwal.;Dong Han.;Nicholas van Buuren.;Peiwen Wu.;Becket Feierbach.;Jaw-Town Lin.;Cheng-Hao Tseng.;Chi-Yi Chen.;Bryan Downie.;Hongmei Mo.;Lauri Diehl.;Li Li.;Simon P Fletcher.;Scott Balsitis.;Ricardo Ramirez.;Vithika Suri.;Yao-Chun Hsu.
来源: Gut. 2025年74卷4期628-638页
The impact of nucleos(t)ide analogues on intrahepatic viral burden and immune microenvironment in patients with chronic hepatitis B (CHB) is not clear.
|